These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23484812)

  • 1. Biotechnology financing, not acquisitions, for filling the pharma pipeline - a sustaining strategy.
    Fernandes P
    Expert Opin Drug Discov; 2007 Jul; 2(7):917-21. PubMed ID: 23484812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financing development stage biotechnology companies: RMs vs. IPOs.
    Ahn MJ; Couch RB; Wu W
    J Health Care Finance; 2011; 38(1):32-54. PubMed ID: 22043645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharma Success in Product Development—Does Biotechnology Change the Paradigm in Product Development and Attrition.
    Evens RP
    AAPS J; 2016 Jan; 18(1):281-5. PubMed ID: 26475480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White biotechnology: ready to partner and invest in.
    Kircher M
    Biotechnol J; 2006; 1(7-8):787-94. PubMed ID: 16897821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partnership between small biotech and big pharma.
    Wiederrecht GJ; Hill RG; Beer MS
    IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late-stage Product Development and Approvals by Biotechnology Companies After Initial Public Offering, 1997-2016.
    McNamee LM; Cleary EG; Zhang S; Salim U; Ledley FD
    Clin Ther; 2021 Jan; 43(1):156-171.e15. PubMed ID: 33380363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD; Califf RM; Schulman KA
    Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investing in medical device companies.
    Benson B; Mutsch E
    Med Device Technol; 1993 Nov; 4(9):44-6. PubMed ID: 10146504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.
    Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E
    PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Company stock prices before and after public announcements related to oncology drugs.
    Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
    J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotechnology stock prices before public announcements: evidence of insider trading?
    Overgaard CB; van den Broek RA; Kim JH; Detsky AS
    J Investig Med; 2000 Mar; 48(2):118-24. PubMed ID: 10736971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotechnology in South Africa.
    Cloete TE; Nel LH; Theron J
    Trends Biotechnol; 2006 Dec; 24(12):557-62. PubMed ID: 17070947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tales of two medical startup companies.
    Bottles K
    Physician Exec; 2001; 27(5):80-2. PubMed ID: 12881911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling the impacts of FDA Breakthrough Therapy Designation: a dual-perspective examination of economic and developmental outcomes for biotechnology companies.
    Williamson J; Spicer AJ; Louramo E; Jalkanen J
    Drug Discov Today; 2024 Apr; 29(4):103919. PubMed ID: 38365000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.